<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094284</url>
  </required_header>
  <id_info>
    <org_study_id>2021.459</org_study_id>
    <nct_id>NCT05094284</nct_id>
  </id_info>
  <brief_title>BioFreedom Ultra Registry</brief_title>
  <official_title>BioFreedom Ultra Stent in Hong Kong All Comers Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the past three decades, coronary stent struts have been made progressively thinner. Thin&#xD;
      strut drug-eluting stents (DES) performed better than their thicker counterparts in a recent&#xD;
      study[1]. Thinner struts discourage abnormal coronary flow after implantation and associated&#xD;
      with greater flexibility, deliverability and better clinical outcomes. Lower strut thickness&#xD;
      may be particularly advantageous in small target vessels because thicker struts and smaller&#xD;
      minimum in-stent lumen diameter are independent predictors of in-stent restenosis. BioFreedom&#xD;
      Ultra is a thin strut (84μm), cobalt-chromium, carrier-free drug-coated stent with Biolimus&#xD;
      A9 drug. The BioFreedom Ultra stent is intended for percutaneous coronary intervention (PCI)&#xD;
      for high-bleeding-risk (HBR) patients treated with 1-month dual antiplatelet therapy.&#xD;
      BioFreedom Ultra received CE mark in October 2020 supported by the LEADERS FREE III trial&#xD;
      which enrolled 400 HBR patients using the same inclusion criteria as the LEADERS FREE&#xD;
      randomized trial [2]. LEADERS FREE III is a single-arm trial, with all patients treated using&#xD;
      the BioFreedom Ultra stent. The data was compared to the BioFreedom stainless steel&#xD;
      drug-coated stent (DCS-StS) and bare-metal stent (BMS) groups from LEADERS FREE [3]. The&#xD;
      primary safety endpoint of the trial was a composite of cardiac death, myocardial infarction,&#xD;
      or definite/probable stent thrombosis. The primary efficacy endpoint was clinically driven&#xD;
      target lesion revascularization. The study found that the BioFreedom Ultra was non-inferior&#xD;
      to the DCS-StS for safety and superior to the BMS for efficacy [4]. Definite or probable&#xD;
      stent thrombosis at 1 year in this HBR population was only 1%. Recently, the Biofreedom QCA&#xD;
      randomized trial compared the Biofreedom Ultra with the stainless steel version (DCS-StS) in&#xD;
      an all-comer population. In this prospective, single-blind non-inferiority randomized (1:1)&#xD;
      trial, BioFreedom Ultra was non-inferiority for late lumen loss at 9 months in comparison&#xD;
      with DCS-StS [5]. REFERENCES&#xD;
&#xD;
        1. Buiten RA, et al. BIO-RESORT Trial, JAMA Cardiol. 2019;4(7):659-669.&#xD;
&#xD;
        2. National Library of Medicine (U.S.). (2017, November 8 - 2022, December 30). A Study&#xD;
           Evaluating the Safety and Efficacy of the BioFreedom™ Biolimus A9™ Coated Cobalt&#xD;
           Chromium Coronary Stent System in Patients at High Risk of Bleeding.&#xD;
&#xD;
           Identifier: NCT03118895. https://clinicaltrials.gov/ct2/show/NCT03118895&#xD;
&#xD;
        3. Urban P, et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding&#xD;
           Risk, NEJM. 2015; 373:2038-2047.&#xD;
&#xD;
        4. Garot P, et al. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free&#xD;
           Drug-Coated Stents, JACC.&#xD;
&#xD;
      2017; 69(2):162-171. 5. Sabate M. BioFreedom QCA trial. PCR e-course 2020. (presented at&#xD;
      EuroPCR 2020 but unpublished).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past three decades, coronary stent struts have been made progressively thinner. Thin&#xD;
      strut drug-eluting stents (DES) performed better than their thicker counterparts in a recent&#xD;
      study[1]. Thinner struts discourage abnormal coronary flow after implantation and associated&#xD;
      with greater flexibility, deliverability and better clinical outcomes. Lower strut thickness&#xD;
      may be particularly advantageous in small target vessels because thicker struts and smaller&#xD;
      minimum in-stent lumen diameter are independent predictors of in-stent restenosis. BioFreedom&#xD;
      Ultra is a thin strut (84μm), cobalt-chromium, carrier-free drug-coated stent with Biolimus&#xD;
      A9 drug. The BioFreedom Ultra stent is intended for percutaneous coronary intervention (PCI)&#xD;
      for high-bleeding-risk (HBR) patients treated with 1-month dual antiplatelet therapy.&#xD;
      BioFreedom Ultra received CE mark in October 2020 supported by the LEADERS FREE III trial&#xD;
      which enrolled 400 HBR patients using the same inclusion criteria as the LEADERS FREE&#xD;
      randomized trial [2]. LEADERS FREE III is a single-arm trial, with all patients treated using&#xD;
      the BioFreedom Ultra stent. The data was compared to the BioFreedom stainless steel&#xD;
      drug-coated stent (DCS-StS) and bare-metal stent (BMS) groups from LEADERS FREE [3]. The&#xD;
      primary safety endpoint of the trial was a composite of cardiac death, myocardial infarction,&#xD;
      or definite/probable stent thrombosis. The primary efficacy endpoint was clinically driven&#xD;
      target lesion revascularization. The study found that the BioFreedom Ultra was non-inferior&#xD;
      to the DCS-StS for safety and superior to the BMS for efficacy [4]. Definite or probable&#xD;
      stent thrombosis at 1 year in this HBR population was only 1%. Recently, the Biofreedom QCA&#xD;
      randomized trial compared the Biofreedom Ultra with the stainless steel version (DCS-StS) in&#xD;
      an all-comer population. In this prospective, single-blind non-inferiority randomized (1:1)&#xD;
      trial, BioFreedom Ultra was non-inferiority for late lumen loss at 9 months in comparison&#xD;
      with DCS-StS [5]. REFERENCES&#xD;
&#xD;
        1. Buiten RA, et al. BIO-RESORT Trial, JAMA Cardiol. 2019;4(7):659-669.&#xD;
&#xD;
        2. National Library of Medicine (U.S.). (2017, November 8 - 2022, December 30). A Study&#xD;
           Evaluating the Safety and Efficacy of the BioFreedom™ Biolimus A9™ Coated Cobalt&#xD;
           Chromium Coronary Stent System in Patients at High Risk of Bleeding.&#xD;
&#xD;
           Identifier: NCT03118895. https://clinicaltrials.gov/ct2/show/NCT03118895&#xD;
&#xD;
        3. Urban P, et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding&#xD;
           Risk, NEJM. 2015; 373:2038-2047.&#xD;
&#xD;
        4. Garot P, et al. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free&#xD;
           Drug-Coated Stents, JACC.&#xD;
&#xD;
      2017; 69(2):162-171. 5. Sabate M. BioFreedom QCA trial. PCR e-course 2020. (presented at&#xD;
      EuroPCR 2020 but unpublished).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">September 2, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>MACE events</measure>
    <time_frame>12 months post index procedure</time_frame>
    <description>12-months cumulative hierarchical incidence of major adverse cardiac events (MACE) defined as: cardiac death, non-fatal myocardial infarction (MI) and clinically indicated target vessel revascularization (TVR). In order to minimize bias in assessing MACE outcomes, these events will be adjudicated by an independent observer.</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioFreedom Ultra</intervention_name>
    <description>this is a registry only</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Being an observational registry aiming to quantify effect estimates without direct&#xD;
        comparisons to other devices, we used confidence interval profiling for sample size&#xD;
        justification. Assuming an 8.43% MACE rate at 1 year [5], 95% confidence intervals computed&#xD;
        with the adjusted Wald method would be 5.4% to 11.5% for a 300 patient sample. Given that&#xD;
        the registry aims to reflect real-world patients and practice, 300 patients will be&#xD;
        enrolled in this registry.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        This is an &quot;all comers&quot; registry and patient who will be enrolled have to meet following&#xD;
        criteria:&#xD;
&#xD;
          -  Patient must be at least 18 years of age&#xD;
&#xD;
          -  Patient must have indication to percutaneous coronary intervention including:&#xD;
&#xD;
               -  Stable angina or evidence of myocardial ischemia with stress echocardiography/&#xD;
                  myocardial SPECT/exercise test, or&#xD;
&#xD;
               -  Unstable angina / non ST-elevation myocardial infarction, OR&#xD;
&#xD;
               -  ST-elevation myocardial infarction with de novo culprit lesion.&#xD;
&#xD;
          -  Presence of one or more coronary artery stenosis &gt;50% with reference diameter&#xD;
             2.0-6.0mm which can be covered by one or multiple stents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance to any of the device components&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Participating in other trial before reaching primary endpoint&#xD;
&#xD;
          -  Planned surgery within 1 month of PCI unless dual antiplatelet therapy is maintained&#xD;
             throughout the peri-surgical period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sushanna Lai</last_name>
      <phone>(852) 35051518</phone>
      <email>sushannalai@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Sabaté M, Okkels Jensen L, Tilsted HH, Moreno R, García Del Blanco B, Macaya C, Pérez de Prado A, Cequier À, Pérez-Fuentes P, Schütte D, Costa RA, Stoll HP, Flensted Lassen J. Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. EuroIntervention. 2021 Jun 25;17(3):233-239. doi: 10.4244/EIJ-D-20-01162.</citation>
    <PMID>33433389</PMID>
  </reference>
  <results_reference>
    <citation>Buiten RA, Ploumen EH, Zocca P, Doggen CJM, van der Heijden LC, Kok MM, Danse PW, Schotborgh CE, Scholte M, de Man FHAF, Linssen GCM, von Birgelen C. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial. JAMA Cardiol. 2019 Jul 1;4(7):659-669. doi: 10.1001/jamacardio.2019.1776.</citation>
    <PMID>31111862</PMID>
  </results_reference>
  <results_reference>
    <citation>Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC; LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med. 2015 Nov 19;373(21):2038-47. doi: 10.1056/NEJMoa1503943. Epub 2015 Oct 14.</citation>
    <PMID>26466021</PMID>
  </results_reference>
  <results_reference>
    <citation>Garot P, Morice MC, Tresukosol D, Pocock SJ, Meredith IT, Abizaid A, Carrié D, Naber C, Iñiguez A, Talwar S, Menown IBA, Christiansen EH, Gregson J, Copt S, Hovasse T, Lurz P, Maillard L, Krackhardt F, Ong P, Byrne J, Redwood S, Windhövel U, Greene S, Stoll HP, Urban P; LEADERS FREE Investigators. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. J Am Coll Cardiol. 2017 Jan 17;69(2):162-171. doi: 10.1016/j.jacc.2016.10.009. Epub 2016 Oct 30.</citation>
    <PMID>27806919</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Bryan Ping Yen YAN</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>BioFreedom Ultra</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>percautaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

